| 货号 | HP628016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Humanized |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q9NYJ7 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | SC0001-SCX, SC0002, 1613313-01-1 |
| 背景 | Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). • Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629 • Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer., PMID:30894499 • DLL3: an emerging target in small cell lung cancer., PMID:31215500 • Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study., PMID:36689692 • AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer., PMID:33203642 • DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms., PMID:35983951 • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo., PMID:26311731 • IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models., PMID:36951942 • HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors., PMID:38670552 • Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)., PMID:37694295 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Rovalpituzumab.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
